No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
4-methylpyrazole |
Fomepizole |
D00707 |
3件: ADH1A, ADH1B, ADH1C |
8件: Chemical carcinogenesis, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / Gluconeogenesis, Metabolic pathways, Metabolism of xenobiotics by cytochrome P450, Retinol metabolism, Tyrosine metabolism |
1件: 301 |
2 |
Acu-4429 |
- |
- |
- |
- |
1件: 301 |
3 |
Alk-001 |
- |
- |
- |
- |
1件: 301 |
4 |
Alk-001 (no generic name) |
- |
- |
- |
- |
1件: 301 |
5 |
Antioxidants |
- |
- |
- |
- |
4件: 90, 298, 301, 310 |
6 |
Arc1905 |
- |
- |
- |
- |
1件: 301 |
7 |
Arc1905 20 mg/ml |
- |
- |
- |
- |
1件: 301 |
8 |
Avacincaptad pegol |
Avacincaptad pegol |
- |
- |
- |
1件: 301 |
9 |
Cholesterol |
Cholesterol |
D00040 |
- |
- |
7件: 19, 90, 160, 259, 261, 301, 310 |
10 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
11 |
Docosahexaenoic acid (dha) dietary supplement |
Doconexent |
- |
- |
- |
1件: 301 |
12 |
Emixustat |
Emixustat |
D10348 |
- |
- |
1件: 301 |
13 |
Emixustat hydrochloride |
Emixustat |
D10348 |
- |
- |
1件: 301 |
14 |
Emixustat hydrochloride (acu-4429) |
Emixustat |
D10348 |
- |
- |
1件: 301 |
15 |
Hesc-rpe |
- |
- |
- |
- |
1件: 301 |
16 |
Interferon gamma-1b |
- |
- |
- |
- |
7件: 65, 85, 90, 228, 299, 301, 326 |
17 |
Lentiviral vector containing abca4 gene |
- |
- |
- |
- |
1件: 301 |
18 |
Ma09-hrpe |
- |
- |
- |
- |
1件: 301 |
19 |
Madeos |
- |
- |
- |
- |
1件: 301 |
20 |
Over the counter dha/epa dietary supplementation |
- |
- |
- |
- |
1件: 301 |
21 |
Ranibizumab |
Ranibizumab |
D05697 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
4件: 34, 166, 227, 301 |
22 |
Ranibizumab injection (0.5 mg) |
Ranibizumab |
D05697 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
2件: 166, 301 |
23 |
Saffron supplementation |
- |
- |
- |
- |
1件: 301 |
24 |
Sar422459 |
- |
- |
- |
- |
1件: 301 |
25 |
Sar422459 administered in previous study tdu13583 |
- |
- |
- |
- |
1件: 301 |
26 |
Stem/progenitor cells transplantation |
- |
- |
- |
- |
2件: 90, 301 |
27 |
Vett lentiviral con gene abca4 |
- |
- |
- |
- |
1件: 301 |
28 |
Zimura |
- |
- |
- |
- |
1件: 301 |